Health Trials

Center-involved Diabetic Macular Edema

3

Review clinical trials related to Center-involved Diabetic Macular Edema. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema

Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: OcugenUpdated: Jul 31, 2026Locations: 5
Eligibility criteria

Diagnosis of Type 1 or Type 2 Diabetes Mellitus [+6]

Presence of any condition that prevent clear visualization of retina (e.g., sign... [+10]

Read more
Status: Recruiting

Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema

This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: The General Authority for Teaching Hospitals and InstitutesUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

Age ≥18 years. [+3]

Monocular eyes. [+12]

Read more
Status: Recruiting

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement in patients with diabetic macular edema. The main question the study aims to answer is: Does dapagliflozin reduce the thickness of the macula when combined with the standard of care intravitreal anti-VEGF therapy more than the intravitreal anti-VEGF therapy alone?

Participants needed: 56
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Alexandria UniversityUpdated: Jun 19, 2025Locations: 1
Eligibility criteria

Type II diabetes mellitus patients, treated with premixed insulin and metformin,... [+4]

Patients below 18 years old and patients above 85 years old [+29]

Read more